Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer

Exclusion Criteria

• •Subject has any evidence of metastasis.
• •Subject received hormones, including luteinizing hormone-releasing hormone agonists, antiandrogens, or 5 α-reductase inhibitors at any time prior to study screening.
• •Subject has received prior radiation therapy or chemotherapy for prostate cancer.
• •Subject has received systemic steroid therapy within 14 days.
• •Subject has a history of stage III or greater cancer, excluding prostate cancer.
• •Subjects with a history of basal or squamous cell skin cancers are allowed, provided that the subject was adequately treated and is disease-free at the time of study screening.
• •Subjects with a history of stage I or II cancer must have been adequately treated and been disease-free for ≥ 3 years prior to study screening.